The FDA finalized guidance treating content from drug companies’ apps as drug labeling, replacing its 2023 draft on Oct. 21, 2026.
The US Food and Drug Administration (FDA) has finalized guidance on apps and software that drug companies give out with prescription medicines. It treats what the software shows patients and doctors as drug labeling, and comments stay open at any time.
The FDA announced the final guidance in the Federal Register on Oct. 21, 2026, ending a process that began with a draft on Sept. 19, 20231. It covers drug companies, called sponsors, that distribute software for use with prescription drugs or drug-led drug-device combination products1. The guidance is nonbinding, and the public may comment on it at any time under docket FDA-2023-D-24822.
| At a glance | Details |
|---|---|
| What was published | Final guidance for industry, "Regulatory Considerations for Prescription Drug Use-Related Software" |
| Published on | 21 October 2026 (posted by FDA on 20 October 2026) |
| Who must comply | Drug sponsors that distribute software for use with their prescription drugs |
| Feedback deadline / Effective date | Comments accepted at any time. No fixed compliance date is set |
| Final rules / Next milestone | Guidance is final. It replaces the September 2023 draft |
What is drug use-related software, and why does it matter?
The guidance covers software that a drug sponsor, or a developer working for it, distributes3. The software must produce output that supplements, explains, or relates to one of the sponsor’s drugs3. This applies whether or not the software is also regulated as a medical device1.
What the guidance covers
| Dimension | Provision |
|---|---|
| Who it covers | Software distributed by or for a drug sponsor |
| What it covers | Output that supplements, explains or relates to the sponsor’s drugs |
| How output is treated | As a type of prescription drug labeling |
| Outside scope | Software not distributed by or for a sponsor |
Output means any content the software shows an end user, such as a patient, caregiver or health care practitioner1. The FDA considers that output a type of prescription drug labeling1. That brings app screens and messages under the same truthfulness rules that apply to printed drug information.
The FDA lists possible uses such as tracking doses, giving individual dosing advice, predicting treatment response and managing side effects3. Software made by an outside developer, not distributed by or for a sponsor, falls outside the guidance3. Software whose content is purely about a disease, not a specific drug, is generally also outside it3.
How the FDA sorts software output
The agency splits drug labeling into two groups3. FDA-required labeling is reviewed and approved as part of a drug’s marketing application3. Promotional labeling is generally everything else3.
To decide which group an app’s output belongs in, the FDA will weigh three questions3.
| Question the FDA asks | Why it matters |
|---|---|
| Is the software essential to safe and effective drug use? | It may need describing in the prescribing information3 |
| Does evidence show a meaningful improvement in a clinical outcome? | FDA decides this based on evidence the sponsor provides3 |
| Does the software rely on data from a device? | This marks it as device-connected rather than standalone3 |
Device-connected functions use data sent from the device part of a combination product3. Standalone functions are all the rest, such as features that rely on data typed in by users3.
What changed from the 2023 draft
The FDA says it considered public comments on the draft before finalizing1. The final version makes four main changes1.
- It clarifies how the rules apply to standalone software functions1.
- It adds a decision tree to guide sponsors through labeling choices1.
- It gives example wording for the prescribing information for both device-connected and standalone software1.
- It recommends a statement in the prescribing information when device-connected software shows no meaningful clinical improvement1.
The prescribing information is the official drug summary for doctors. It must hold the essential scientific facts needed for safe and effective use3. It must also be accurate, up to date, and not promotional or misleading3.
What changes for drug sponsors
The guidance explains how the prescribing information should describe software functions3. It also explains when and how sponsors should submit software output to the FDA for review1. Sponsors are encouraged to discuss planned software functions with the relevant FDA review division3.
Promotional output carries its own duties. Promotional labeling must be truthful, balanced on benefits and risks, and reveal material facts3. Firms that send out promotional materials must also submit them to the FDA on Form FDA 22533.
The guidance does not change device rules3. Some software functions may still meet the legal definition of a medical device and face device requirements3.
Legal status and enforcement
FDA guidance documents do not create legally enforceable duties on their own3. Firms may use another approach if it meets the applicable laws and regulations1. The FDA found the action is neither a regulatory nor a deregulatory action under Executive Order 141921.
From draft to final
The underlying law still bites. A drug shipped across state lines with false or misleading labeling is misbranded under the Federal Food, Drug, and Cosmetic Act3. Because app output counts as labeling, that standard now clearly reaches software content.
Key terms in plain words
| Term | Meaning |
|---|---|
| Sponsor | A company that seeks or holds FDA approval for a drug |
| End-user output | Any content an app shows a patient, caregiver or doctor |
| Prescribing information | The official FDA-approved drug summary for health professionals |
| Combination product | A product that contains both a drug and a device part |
| Standalone software | Software features not fed by data from a device |
| Misbranded | Sold with false or misleading labeling, which breaks federal law |
The guidance was announced on Oct. 21, 2026, and comments remain open at any time under docket FDA-2023-D-24822.
Sources
- ↩ Federal Register :: Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability https://www.federalregister.gov/documents/2026/10/21/2026-21516/regulatory-considerations-for-prescription-drug-use-related-software-guidance-for-industry
- ↩ Regulatory Considerations for Prescription Drug Use-Related Software | FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescription-drug-use-related-software
- ↩ Regulatory Considerations for Prescription Drug Use- Related Software https://www.fda.gov/media/172165/download